Oesophageal Adenocarcinoma clinical trials

Explore recruiting oesophageal adenocarcinoma clinical trials.

Recruiting oesophageal adenocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Oesophageal Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

MEtformin as a MEtabolic iNTervention in Oesophageal adenocarcinomas to improve response to neoadjuvant chemoradiotherapy

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859)

Denmark, France, Ireland, Czechia, Poland, Spain +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection

Germany, Sweden, Portugal, Netherlands, Poland, France +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

C5731004 - SGNDV-004 - A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination with Other Anticancer Therapies in Solid Tumors

Italy, Germany, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Oesophageal Adenocarcinoma trials by city

Oesophageal Adenocarcinoma in Toronto Oesophageal Adenocarcinoma in Vancouver Oesophageal Adenocarcinoma in Montreal Oesophageal Adenocarcinoma in Calgary Oesophageal Adenocarcinoma in Edmonton Oesophageal Adenocarcinoma in Ottawa Oesophageal Adenocarcinoma in Winnipeg Oesophageal Adenocarcinoma in Quebec City Oesophageal Adenocarcinoma in Hamilton Oesophageal Adenocarcinoma in Kitchener Oesophageal Adenocarcinoma in London Oesophageal Adenocarcinoma in Halifax Oesophageal Adenocarcinoma in New York Oesophageal Adenocarcinoma in Los Angeles Oesophageal Adenocarcinoma in Chicago Oesophageal Adenocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease